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72 Abstract Smith–Lemli–Opitz syndrome (SLOS), a multiple congenital
anomaly with severe mental retardation, is caused by decreased
activity of 7-dehydrocholesterol reductase. Fifteen Hungarian
patients were diagnosed with SLOS on the basis of clinical
symptoms, serum cholesterol, 7-dehydrocholesterol, and molecular
genetic testing. Their age at the time of diagnosis in mild SLOS (n  
= 4, clinical score <20) was 0.5–18 years, cholesterol was 2.37  ± 
0.8 mmol/L, and 7DHC was 0.38  ± 0.14 mmol/L. In the group of
typical SLOS (n  = 7, score 20–50), the diagnosis was set up earlier
(age of 0.1–7 years); t-cholesterol was 1.47  ± 0.7 mmol/L, and 7DHC
was 0.53  ± 0.20 mmol/L. Patients with severe SLOS (n  = 4, clinical
score  > 50) died as newborns and had the lowest t-cholesterol (0.66  ± 
0.27 mmol/L), and 7DHC was 0.47  ± 0.14 mmol/L. Correlation
coefficient with clinical severity was 0.74 for initial t-cholesterol and
0.669 for Cho/7DHC. Statistically significant difference was
between the initial t-cholesterol of mild and severe SLOS (p  = 0.01),
and between the Cho/7DHC ratios of groups (p  = 0.004). In severe
SLOS, the percentage of α-lipoprotein was significantly lower than
in typical (p  = 0.003) and mild SLOS (p  = 0.004). Although serum
albumin, total bil irubin, and hemostasis parameters remained in
the reference range during cholesterol supplementation (n  = 10)
combined with statin therapy (n  = 9), increase of aspartate
aminotransferase and alanine aminotransferase in 50 % of the
patients probably refers to a reversible alteration of l iver function;
therefore, statin therapy was suspended. Conclusion: l i fe
expectancy is fundamentally determined by the initial t-cholesterol,
but dehydrocholesterol and α-lipoprotein have prognostic value.
Accumulation of hepatotoxic DHC may inhibit the synthesis of
α-lipoproteins, decreasing the reverse cholesterol transport. During
statin therapy, we suggest monitoring of l ipid parameters and liver
function.
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15 Abstract Smith–Lemli–Opitz syndrome (SLOS), a multiple
16 congenital anomalywith severe mental retardation, is caused by
17 decreased activity of 7-dehydrocholesterol reductase. Fifteen
18 Hungarian patients were diagnosed with SLOSQ2 on the basis of
19 clinical symptoms, serum cholesterol, 7-dehydrocholesterol,
20 and molecular genetic testing. Their age at the time of diagnosis
21 in mild SLOS (n=4, clinical score <20) was 0.5–18 years,
22 cholesterol was 2.37±0.8 mmol/L, and 7DHC was 0.38±
23 0.14 mmol/L. In the group of typical SLOS (n=7, score
24 20–50), the diagnosis was set up earlier (age of 0.1–7 years);
25 t-cholesterol was 1.47±0.7 mmol/L, and 7DHC was 0.53±
26 0.20 mmol/L. Patients with severe SLOS (n=4, clinical
27score>50) died as newborns and had the lowest t-cholesterol
28(0.66±0.27 mmol/L), and 7DHC was 0.47±0.14 mmol/L.
29Correlation coefficient with clinical severity was 0.74 for initial
30t-cholesterol and 0.669 for Cho/7DHC. Statistically significant
31difference was between the initial t-cholesterol of mild and
32severe SLOS (p=0.01), and between the Cho/7DHC ratios of
33groups (p=0.004). In severe SLOS, the percentage of α-
34lipoprotein was significantly lower than in typical (p=0.003)
35and mild SLOS (p=0.004). Although serum albumin, total
36bilirubin, and hemostasis parameters remained in the reference
37range during cholesterol supplementation (n=10) combined
38with statin therapy (n=9), increase of aspartate aminotransfer-
39ase and alanine aminotransferase in 50 % of the patients prob-
40ably refers to a reversible alteration of liver function; therefore,
41statin therapy was suspended. Conclusion: life expectancy is
42fundamentally determined by the initial t-cholesterol, but
43dehydrocholesterol and α-lipoprotein have prognostic value.
44Accumulation of hepatotoxic DHCmay inhibit the synthesis of
45α-lipoproteins, decreasing the reverse cholesterol transport.
46During statin therapy, we suggest monitoring of lipid parame-
47ters and liver function.
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79 Introduction
80 The Smith–Lemli–Opitz syndrome (OMIM 270400), an au-
81 tosomal recessive, severe developmental disorder with multi-
82 ple congenital anomalies, is caused by a defect of cholesterol
83 biosynthesis [3, 12, 20–22]. The syndrome was first reported
84 by Smith et al. in 1964 and was characterized by a dysmorphic
85 face, microcephaly, hypospadiasis, and severe growth retar-
86 dation [26]. The cause of Smith–Lemli–Opitz syndrome
87 (SLOS) is the defective function of the 7-dehydrocholesterol
88 reductase (DHCR7) enzyme which catalyzes the last step of
89 cholesterol biosynthesis [7, 32]. This enzyme is responsible
90 for the transformation of 7-dehydrocholesterol to cholesterol.
91 Cholesterol is an important component of the cell membrane,
92 mitochondrial membrane, and myelin formation in the brain,
93 spinal cord, and peripheral nervous system. Cholesterol acts
94 also as a precursor for bile acids and steroid hormones, and
95 plays an important role in the embryonic hedgehog signaling
96 mechanism during embryogenesis as well [13]. For phenotyp-
97 ic characterization, the modified Bialer scoring system of
98 Kelley and Hennekam has been used which weight embryo-
99 logically separate organ systems equally [12, 13].
100 Calculation of clinical severity scores is based on evalu-
101 ation of anatomical abnormalities in ten embryologically
102 separated organs (brain, oral region, eye, heart, kidney, liver,
103 lung, bowel, and genitals) [13]. In 1998, the human DHCR7
104 gene was cloned by three different groups [4, 35, 36]. Over
105 140 different mutations in the DHCR7 gene have been
106 published to date [39, 40 and Human Gene Mutation Data-
107 base]. For the treatment of the disease, during the past
108 20 years, different therapeutic approaches were applied such
109 as cholesterol substitution, with or without bile acids, and
110 simvastatin that decreases the level of 7DHC and enhances
111 the residual activity of the DHCR7, reportedly with im-
112 provement in both biochemical parameters and clinical
113 symptoms [7, 8, 18, 32]. Recently, the efficiency of choles-
114 terol supplementation has been debated [5, 25], and statins
115 cannot be considered as a safety approach in each SLO
116 patient because of potential side effects [28].
117 In the past, the diagnosis of SLO syndrome was estab-
118 lished mainly on the basis of characteristic phenotypic fea-
119 tures, including severe mental and somatic retardation. The
120 wide range of gene mutations in SLO syndrome and alter-
121 ation of biochemical parameters have been described in
122 different populations [2, 27]. A new mutation of SLO
123syndrome in our first patient was identified by L. Kozak
124and his coworkers [31]. Very recently, we published a
125paper [1] on the genetic background of the Hungarian
126patients with SLOS. Similar to the finding of Porter
127[21], we did not find a strong connection between the
128genotype and phenotype. Therefore, the relation between
129biomarkers and clinical feature was investigated in di-
130agnostic and therapeutic aspects.
131Patients and methods
132During the last decade, 15 patients (age of 0.1–18 years,
133eight males and seven females) were diagnosed with SLO
134syndrome in Hungary, the first case in 2002 [30]. After
135observation of clinical symptoms, their diagnosis was
136proved by serum 7DHC level. Anatomical abnormalities
137of ten embryologically separated organs (brain, oral re-
138gion, acral, eye, heart, kidney, liver, lung, bowel, and
139agenitals) have been scored [13]. On the base of clinical
140severity scores, patients were assigned to three groups:
141patients with mild SLOS were defined by a score below
14220, typical SLOS means 20–50 scores, and a score above
14350 means a severe type of SLO syndrome [12, 13]. The
144patients enrolled into the mild group are still alive (n=4;
145age when the diagnosis was set up, 0.5–18 years). In the
146typical SLOS group (n=7; age at diagnosis, 0.1–7 years),
147two children lived less than 2 years of age; five children
148are still alive. All patients with severe SLOS died in the
149newborn period (n=4, age<2 months). After setting up
150the diagnosis, all patients received cholesterol substitution
151(n=10, Cholesterol Module, 50–250 mg/kg/day, Nutricia;
152no 18.012). It was completed with statin therapy in nine
153patients. Dosage of the statin was 0.2–0.4 mg/kg/day, and
154clinical state and efficiency of therapy were monitored by
155regular clinical checkup in 3- to 6-month periods includ-
156ing the evaluation of clinical condition, anthropometric
157parameters, serum cholesterol, 7DHC level, liver enzymes
158(aspartate aminotransferase (AST), alanine aminotransfer-
159ase (ALT), lactate dehydrogenase (LDH), alkaline phos-
160phatase, gamma-glutamyltransferase (GGT)), and creatine
161kinase (CK) activity. Statin therapy was suspended in five
162patients because of the side effects.
163Rapid determination of 7DHC in serum was performed
164by the modified UV spectrophotometric method of Honda et
165al. [6] and was compared with the gas chromatography–
166mass spectrometry (GC/MS) method described by Kelly
167[10]. Serum samples of the patients were stored frozen at
168−20 °C until use (∼2 weeks). A total of 200 μL serum was
169extracted with 1.6 mL of c-hexane/i-propanol mixture (3:1).
170Humatrol normal serum (Human, Magdeburg, Germany)
171was used as negative control. For calibration, 200 μL ali-
172quot of negative control serum and 100 μL of 400 mg/L
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173 7DHC stock solution (c-hexane/i-propanol, 3:1) were
174 mixed, and then 1.5 mL extracting solution was added to
175 it. All samples were covered and centrifuged at 400×g for
176 5 min. The absorbance of clear supernatant was measured at
177 285 nm. For reagent, blank c-hexane/i-propanol, 3:1, was
178 used. The between-run and within-run coefficients of varia-
179 tion were <10 %. The detection limit of this method is about
180 10 mg/L (or 5 mg/L when using 400 μL of serum), and it is
181 linear in the range of 10–400 mg/L. The t-cholesterol/7-
182 dehydrocholesterol (7-DHC) ratio was calculated in the
183 same unit (in milligram per liter). These 7-DHC concentra-
184 tions were compared to those obtained by a published GC/
185 MS method [10]. When we have compared the UV method
186 with GC in ten samples (LKH Graz, Austria), the same
187 samples proved to be positive although the UV method
188 resulted in lower 7-DHC values. Serum total cholesterol
189 level was determined by a routinely used enzymatic color-
190 imetric assay (Modular, Roche Ltd, Mannheim, Germany).
191 Therefore, we compared total cholesterol (Q5 cholesterol oxi-
192 dase (CHOD)–peroxidase (POD)) results with LC-MS, and
193 UV method of 7DHC with LC-MS (7+8DHC) in eight
194 patients. The correlation coefficient was 0.962 between the
195 two cholesterol methods and 0.9477 between (7+8DHC) and
196 7DHC results. The proportion of alpha-, beta-lipoproteins,
197 and kilomicron fractions was analyzed by agarose gel electro-
198 phoresis (Hydragel 15, Sebia, AL Instruments, Lisses,
199 France). Enzyme activities were determined in serum by IFCC
200 (AST, ALT, GGT, CK) or optimized UV kinetic method
201 (LDH) on a Modular P800 analyzer (Roche Ltd, Mannheim).
202 Serum total and conjugated bilirubin was determined by col-
203 orimetric assay and cholesterol by enzymatic colorimetric
204 method (CHOD–POD) on the same analyzer.
205 Statistical comparison of cholesterol, 7DHC, and α-
206 lipoprotein levels among the three groups was carried out
207 by Kruskal–Wallis test. For the cholesterol and α-lipoprotein
208 levels that showed Gaussian distribution, the Bonferroni test
209 was applied for pairwise comparisons.
210 Results
211 The age of patients when the diagnosis was set up was in wide
212 range (0.5–18 years); in the mild-type SLOS group (n=4, clin-
213 ical score <20), the mean level of serum cholesterol was 2.37±
214 0.8 mmol/L and the mean of 7DHC was 0.38±0.14 mmol/L
215 (147±55mg/L). In the group of typical SLOS, diagnosis was set
216 up earlier (age of 0.1–7 years) (n=7; clinical score, 20–50); the
217 mean of serum cholesterol level was 1.47±0.7 mmol/L, and
218 7DHC was 0.53±0.20 mmol/L (202±77 mg/L).
219 Those patients who died as newborns (at the age of less than
220 2 months) were enrolled into the severe SLOS group (n=4,
221 clinical score >50). Their 7DHC level (0.47±0.14 mmol/L;
222 181±52 mg/L) was similar to the typical SLO group with great
223scatter, but their cholesterol level (0.66±0.27 mmol/L) was
224significantly lower than in mild SLOS (2.37±0.8 mmol/L). In
225spite of the limited number of patients, our data refer to the
226prognostic value of initial cholesterol level regarding the life
227expectance.
228Clinical severity scores, genotypes, and initial lipid param-
229eters are listed in Table 1. Correlation between initial serum
230cholesterol and clinical scores is shown in Fig. 1 (n=15;
231regression line, r=0.74). The initial Cho/7DHC ratio showed
232a similar weak inverse relationship with clinical scores
233(r=0.669). Statistical evaluation of the three SLOS groups
234showed significant difference in the initial cholesterol levels
235of the mild and severe SLOS groups (Bonferroni test, p=0.01;
236Fig. 2a). A significant difference could be observed between
237the Cho/7DHC ratios of the groups as well (Kruskal–Wallis
238test, p=0.004; Fig. 2b).
239Lipoprotein gel electrophoresis detected decreased per-
240centage of α-lipoprotein in severe SLOS (7±5 %) compared
241to the age-matched control group 25.4±1.6 % (n=5; age, 0–
2423 years) without lipid disorder or to the typical (31.6±9 %)
243and mild SLOS (33±6 %). Bonferroni test proved that the
244ratio of α-lipoprotein in the severe SLOS group was signif-
245icantly lower than in the typical (p=0.003) and mild SLOS
246group (p=0.004); see Fig. 2c. It might be clinically relevant
247that alpha lipoproteins are hardly detectable by gel electro-
248phoresis in severe SLOS (Fig. 3a), while the distribution of
249lipoproteins is generally normal in mild cases (Fig. 3b).
250Q7Our findings suggest that the initial level of serum cho-
251lesterol fundamentally determines the severity and life ex-
252pectancy in SLOS, and the ratio of Cho/7DHC and α-
253lipoprotein has additional prognostic value.
254Liver function was monitored in those patients who sur-
255vived the age of 1 year (n=10). LDH activity was elevated
256in one patient, and creatine kinase was high in another
257patient—both of them were treated by simvastatin. We have
258observed more cases of elevated AST and ALT activities in
259typical SLOS (n=4/5; age, 6±5.1 years; score, >20) than in
260mild cases (n=1/5; age, 5.1±1 years; score, <20) during
261cholesterol supplementation (n=10) combined with statin
262therapy (n=9). The transaminase activities were twice as
263much in typical SLOS (AST, 50±29 U/L; ALT, 47±25 U/L)
264than in mild type (AST, 23±7 U/L; ALT, 21±21 U/L).
265Besides the similar age in the two groups, we have to notice
266that the duration of therapy was longer (2.9±2.6 years) in
267the typical group compared to the mild SLOS (0.8±1 year).
268Although serum albumin (36.8–47.3 g/L), total bilirubin,
269and the hemostasis parameters remained in the reference
270range, the increase of AST and ALT in 50 % of the patients
271probably refers to a reversible alteration of liver function.
272Increased sensibility of liver in SLOS may be the conse-
273quence of higher DHC level. When statin treatment (sim-
274vastatin, atorvastatin) was suspended in the affected five
275patients, their liver enzyme activities returned to the
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276 reference range—a typical case is demonstrated on Fig. 4.
277 Cholesterol monotherapy was enough to improve total cho-
278 lesterol with 0.5–1 mmol/L in three patients.
279 Discussion
280 The incidence of Smith–Lemli–Opitz syndrome is rang-
281 ing from 1:20,000 to 1:60,000 [11, 17]. Our northern
282 neighboring countries, in the Czech Republic and in the
283 Slovak population, the incidence is even higher: from
284 1:10,000 to 1:20,000 [2]. We could correctly identify
285 15 patients by the rapid determination of 7DHC in serum
286 which was performed with UV spectrophotometry that
287 showed good correlation with the GC/MS method [6,
288 10]. It is important to mention that UV spectrophotome-
289 try is an easy-to-use method but less sensitive compared
290 to GC–MS, and there is a difference between the two
291 methods (2–39 %) as Honda and Batta also described
292 [5]. Our findings are in accordance with the recently
293 emerged and accepted opinion that the initial value of
294 serum cholesterol fundamentally determines the severity,
295 development, and life expectancy of SLOS [25]. The
296 cholesterol/7DHC ratio has additional prognostic value
297 in the classification of SLOS.
298 The decreased ratio of α-lipoproteins detected in se-
299 vere SLO compared to the other types of SLO or to the
300 age-matched control group may be the consequence of
301 cholesterol biosynthesis disorder. On the other hand, the
302 impaired liver function which can be observed in typical
303 and severe SLO because of accumulated toxic dehydro-
304 cholesterol and other sterol metabolites may further in-
305 hibit the synthesis of lipoproteins. As the reactivity of
306 7DHC with oxygene radicals increased [42], a high
307 blood level of 7DHC in severe SLO phenotype tends to
308accelerate lipid peroxidation causing further damage of
309proteins and antioxidant enzymes on the surface of high-
310density cholesterol. Because of an extremely low α-
311lipoprotein level in severe SLOS, we suppose that cho-
312lesterol reverse transport will slow down causing a great-
313er extent of cholesterol deficiency. Q9Although the number
314of our patients is limited and results cannot be evaluated
315properly statistically, our long-run clinical experiences,
316e.g., poor life expectancy, seem to be in accordance with
317this hypothesis.
318Treatment with cholesterol with or without bile acids can
319improve the sterol abnormalities observed in patients with
320SLO syndrome [18, 34]. Introduction of statins in the treat-
321ment of SLO patients is based on the fact that inhibition of
322HMG-CoA reductase results in a decrease in the precursors
y = -14.059x + 55.689
r = 0.74
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Fig. 1 Relation between initial cholesterol level and clinical severity
in SLO syndrome (n=15). Initial cholesterol fundamentally determines
the severity of SLOS and life expectancy
Fig. 2 a Distribution of initial serum cholesterol level in severe,
typical, and mild clinical types of SLOS (box and whiskers). Bonfer-
roni test showed significant difference between the initial cholesterol
levels of mild and severe SLOS groups (p=0.01). b Distribution of
initial serum cholesterol/7DHC ratio in severe, typical, and mild clin-
ical types of SLOS. There was significant difference between the Cho/
7DHC ratios of the patient groups (Kruskal–Wallis test: p=0.004). c
Ratio of initial serum α-lipoprotein in severe, typical, and mild types of
SLOS. Bonferroni test proved that the ratio of α-lipoprotein in severe
SLOS group was significantly lower than in the typical (p=0.003) and
mild SLOS group (p=0.004)
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323 such as 7DHC or 8DHC [8].Q10 Moreover, in in vitro human
324 fibroblast culturing in a cholesterol-deficient medium sup-
325 plemented with statin, an upregulation of the DHCR7
326 activity was detected [24]. The phenomenon that choles-
327 terol substitution in combination with simvastatin treat-
328 ment decreases the level of the abnormally high 7DHC
329 as well as increases the cholesterol level recently is
330 debated. In accordance with Starck, during statin therapy,
331 we observed significant liver function impairment in
332 SLOS which emphasizes the vulnerability of patients
333 with limited liver detoxication capacity, and that needs
334 special attention in therapeutic approach [28]. We agree
335 with Starck et al. that simvastatin treatment in SLOS
336 cannot be considered as a safe approach in each case.
337 When hepatotoxic effect is detected, modification of
338 therapy (e.g., cholesterol supplementation without statin)
339 may be considered which can increase the cholesterol
340and reestablish the liver function [28]. According to
341Haas’ opinion, the mechanism of these therapeutic
342approaches is different: the level of cholesterol can be
343elevated by supplementation, and statins may reduce the
344DHC level which increases the cholesterol/7DHC ratio [5].
345Determination of the lipid parameters in different cat-
346egories of SLO syndrome is essential, because initial
347lipid levels have prognostic value. Monitoring of lipids
348and liver function helps to evaluate the efficiency of
349cholesterol supplementation and detects the side effect
350of statin therapy.
351Although it is generally accepted that SLO syndrome
352has wide genetic variability, and genotype and pheno-
353type are not in close connection, the blood level of
354cholesterol precursor 7DHC and clinical severity depend
355on mutation types [3, 5, 12, 41]. Therefore, biochemical
356markers still have a significant role besides the pheno-
357type in setting up the diagnosis, prognosis, and later in
358the follow-up.
359The early diagnosis is the precondition of the effective
360therapy although the individual results are different with
361strong limitation. Prenatal diagnosis with biochemical
362methods and molecular genetic test are available if the
363disease-causing mutation(s) in the family is known [14,
36415, 20, 23]. Traditional biochemical screening of the
365substrates (7DHC and 8DHC) in serum is not reliable
366for detection of carrier status because there is an overlap
367between the ranges of serum concentrations of cholester-
368ol and 7DHC in carriers and noncarriers; therefore, the
369biochemical testing of fibroblasts (7DHC) or the molec-
370ular genetic analysis of the disease-causing mutations in
371the family is recommended [24].
372Based on the identification of family-specific gene muta-
373tions in the affected families, the prenatal genetic examina-
374tion was introduced in Hungary in 2009. A web page has
375been set up to provide detailed information about the diag-
376nostic and therapeutic possibilities (www.smithlemliopitz.hu). 7
Fig. 3 a Alpha lipoproteins are
hardly detectable in severe
SLOS (patient 13, Sebia gel
electrophoresis). b Percentage
of lipoprotein fractions may be
normal in mild-type SLOS
(patient 1, Sebia gel
electrophoresis)
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Fig. 4 A typical case of statin intolerance in patient 8 during choles-
terol supplementation combined with simvastatin therapy.Q8 When the
liver function and clinical condition were impaired, statin therapy was
finished, and transaminase activities returned to the normal range. The
arrow shows the duration of statin therapy
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